1. Han SY, North JP, Canavan T, Kim N, Yu SS. Merkel cell carcinoma. Hematol Oncol Clin North Am 2012;26:1351-74.
2. Sibley RK, Rosai J, Foucar E, Dehner LP, Bosl G. Neuroendocrine (Merkel cell) carcinoma of the skin. A histologic and ultrastructural study of two cases. The American journal of surgical pathology 1980;4:211-21.
3. Sidhu GS, Feiner H, Flotte TJ, Mullins JD, Schaefler K, Schultenover SJ. Merkel cell neoplasms. Histology, electron microscopy, biology, and histogenesis. The American Journal of dermatopathology 1980;2:101-19.
4. Tilling T, Moll I. Which are the cells of origin in merkel cell carcinoma? J Skin Cancer 2012;2012:680410.
5. Coggshall K, Tello TL, North JP, Yu SS. Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging. Journal of the American Academy of Dermatology 2018;78:433-42.
6. 長谷 哲. メルケル細胞癌. 東京医科大学雑誌 2015;73:331-7.
7. Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. Nature reviews Disease primers 2017;3:17077.
8. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
9. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000;27:118-20.
10. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung. The American Journal of dermatopathology 2006;28:99-104.
11. Miner AG, Patel RM, Wilson DA, et al. Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus. Mod Pathol 2015;28:498-504.
12. Harms PW, Collie AM, Hovelson DH, et al. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol 2016;29:240-8.
13. Erstad DJ, Cusack JC, Jr. Mutational analysis of merkel cell carcinoma. Cancers (Basel) 2014;6:2116-36.
14. Amaral T, Leiter U, Garbe C. Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord 2017.
15. Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell polyomavirus. Curr Opin Virol 2015;11:38-43.
16. Houben R, Adam C, Baeurle A, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. International journal of cancer 2012;130:847-56.
17. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-100.
18. Goh G, Walradt T, Markarov V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 2016;7:3403-15.
19. Harms PW, Vats P, Verhaegen ME, et al. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res 2015;75:3720-7.
20. Cimino PJ, Robirds DH, Tripp SR, Pfeifer JD, Abel HJ, Duncavage EJ. Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma. Mod Pathol 2014;27:1073-87.
21. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute 2011;103:1656-64.
22. Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Applied immunohistochemistry & molecular morphology : AIMM 2013;21:506-10.
23. Nallet-Staub F, Marsaud V, Li L, et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. The Journal of investigative dermatology 2014;134:123-32.
24. Bhatia S, Storer BE, Iyer JG, et al. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. Journal of the National Cancer Institute 2016;108.
25. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single- group, open-label, phase 2 trial. The Lancet Oncology 2016;17:1374-85.
26. D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA oncology 2018;4:e180077.
27. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Annals of diagnostic pathology 2017;29:11-6.
28. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol 2013;228:1676-87.
29. Merten L, Agaimy A, Moskalev EA, et al. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors. Am J Clin Pathol 2016;146:718-26.
30. Van Gele M, Kaghad M, Leonard JH, et al. Mutation analysis of P73 and TP53 in Merkel cell carcinoma. British journal of cancer 2000;82:823-6.
31. Veija T, Sarhadi VK, Koljonen V, Bohling T, Knuutila S. Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas. Cancer genetics 2016;209:30-5.
32. Almeida AM, Queiroz JA, Sousa F, Sousa Â. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug discovery today 2019;24:2044-57.
33. Otter S, Whitaker S, Chatterjee J, Stewart A. The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. Clinical oncology (Royal College of Radiologists (Great Britain)) 2019;31:81-90.
34. Rodríguez-Carunchio L, Soveral I, Steenbergen RD, et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG : an international journal of obstetrics and gynaecology 2015;122:119-27.
35. Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. Journal of the National Cancer Institute 2009;101:938-45.
36. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW. Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. International journal of cancer 2010;126:2240-6.
37. Schrama D, Peitsch WK, Zapatka M, et al. Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. The Journal of investigative dermatology 2011;131:1631-8.
38. Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. The Journal of investigative dermatology 2017;137:819-27.
39. Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba, II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology 2011;58:276-85.
40. Kelsh RN. Sorting out Sox10 functions in neural crest development. BioEssays : news and reviews in molecular, cellular and developmental biology 2006;28:788-98.
41. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene 2003;22:3024-34.
42. Kang Y, Pekmezci M, Folpe AL, Ersen A, Horvai AE. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol 2014;27:55-61.
43. Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 2015;163:811-28.
44. Ito T, Matsubara D, Tanaka I, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer science 2016;107:1527-38.